Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective ch... by Ronald Vender, MD, Irina Turchin, MD, Perla Lansang, MD, Vimal H. Prajapati, MD, Mark Legault, PhD, Maxime Barakat, MD, PhD, MBA, Jensen Yeung, MD

Connect to this object online.